12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Feraheme regulatory update

On Dec. 24, 2012, AMAG said it submitted an sNDA to FDA to expand the indication for Feraheme ferumoxytol to include the treatment of all adult patients with iron deficiency anemia who have failed or could not tolerate oral...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >